Atai Life Sciences N.V. (ATAI)

2,1300 +0,0800 (+3,90%) Alla chiusura: 04:00PM EDT

Atai Life Sciences N.V.

Wallstrasse 16
Berlin 10179
Germany
49 89 2153 9035
https://www.atai.life

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 83

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Christian Angermayer	Founder & Chairman of the Supervisory Board	70k	N/D	1978
Mr. Florian Brand	Co-Founder, MD & CEO	835,44k	N/D	1987
Dr. Srinivas G. Rao M.D., Ph.D.	Co-Founder & Chief Scientific Officer	834,15k	N/D	1969
Ms. Anne Johnson	Chief Financial Officer	N/D	N/D	1969
Dr. Michael Raven Ph.D.	Senior Vice President of Operations	N/D	N/D	N/D
Mr. Frank Stegert	Vice President of Investment & Venture Management	N/D	N/D	1981
Mr. Ryan Barrett	Senior VP, General Counsel & Corporate Secretary	N/D	N/D	1981
Dr. Glenn Short Ph.D.	Senior Vice President of Early Development	N/D	N/D	N/D
Dr. Sahil V. Kirpekar M.D.	Chief Business Officer	N/D	N/D	1986
Dr. Kevin Craig M.D.	Senior Vice President of Clinical Development	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Governance aziendale

L'ISS Governance QualityScore di Atai Life Sciences N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.